What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) jumped 2.5% in the morning session after the company delivered a massive "beat and raise" in its second-quarter report, driven by insatiable demand for its blockbuster GLP-1 weight-loss and diabetes drugs.
The company posted explosive top-line growth, with revenue jumping 47.7% year-over-year to $22.97 billion, blowing past analysts' expectations of $20.62 billion (an 11.4% beat). Profitability was equally impressive, as adjusted earnings of $8.38 per share crushed consensus estimates by 27.3%. The phenomenal performance was largely attributed to surging sales of Mounjaro and Zepbound, proving that Eli Lilly continues to capitalize on the massive total addressable market for obesity treatments.
Buoyed by the momentum, management confidently raised its full-year outlook. The company increased its 2026 revenue guidance by 3% to a midpoint of $86 billion (up from $83.5 billion). It also lifted its full-year adjusted EPS guidance by 5.8% to $36.25 at the midpoint. Notably, management highlighted that they actually raised their underlying EPS forecast by $2.78 per share, though this was offset by $3.03 per share in charges tied to deals executed during the quarter. While operating margins did compress to 39.1% (down from 44.1% a year ago), investors eagerly looked past it, focusing instead on the relentless sales growth that has pushed Eli Lilly's market capitalization to the brink of $1 trillion.
After the initial pop, the shares cooled down to $1,147, up 2.4% from the previous close.
Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 29 days ago when the stock gained 2.8% on the news that JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating. Schott's $1,400 target sits above the roughly $1,243 Street average and signals conviction that Lilly's GLP-1 franchise still has room to run, underpinned by the international expansion of Mounjaro, durable domestic Zepbound demand, and a deep incretin pipeline that includes the oral pill orforglipron (Foundayo) and the triple-agonist retatrutide.
Eli Lilly is up 6.3% since the beginning of the year, and at $1,147 per share, it is trading close to its 52-week high of $1,236 from July 2026. Investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $4,345.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
